New staging system of the fifth Joint National Committee report on the detection, evaluation, and treatment of high blood pressure (JNC-V) alters assessment of the severity and treatment of hypertension.

The fifth Joint National Committee report on the detection, evaluation, and treatment of high blood pressure (JNC-V) introduced a new system of blood pressure classification that incorporated systolic blood pressure (SBP) and established new diastolic blood pressure (DBP) cut points. With the previous JNC classification, subjects were classified according to DBP alone. In this study, our purpose was to assess the effect of the new staging system on the assessment of hypertension severity and to determine whether' the new JNC-V staging system better identifies individuals at risk for hypertensive target-organ damage. We compared the assessment of hypertension severity using JNC-IV with that using JNC-V in 1158 subjects enrolled in the Harlem Hospital Hypertension Clinic database from 1975 to 1992. We used pretreatment DBP to classify subjects according to JNC-IV criteria. These subjects were reclassified into one of the four stages of JNC-V. The assessment of hypertension severity and prevalence of organ damage in subjects who remained in the same category of severity in both systems was compared with damage in subjects who were upstaged. With the JNC-V classification, 321 subjects remained in the same category, and 837 were upstaged. Six hundred and four subjects moved up because of the new cut points of DBP, and 275 were upstaged because of higher SBP. Upstaged subjects had more manifestations of hypertensive target-organ damage. With the new JNC-V classification system, hypertension is assessed as severe or very severe in more individuals than with JNC-IV. Subjects who are upstaged in JNC-V are more likely to have evidence of renal disease and other target-organ damage.

[1]  J. Cutler,et al.  The 1984 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. , 1984, Archives of internal medicine.

[2]  C. Hennekens,et al.  An overview of the meta-analyses of the hypertension treatment trials. , 1991, Archives of internal medicine.

[3]  J. Cutler,et al.  The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. , 1988, Archives of internal medicine.

[4]  H. Dustan,et al.  Renal insufficiency in treated essential hypertension. , 1989, The New England journal of medicine.

[5]  J. Laragh,et al.  The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. , 1986, Journal of the American College of Cardiology.

[6]  Morton H. Maxwell,et al.  Systolic blood pressure as an independent predictor of mortality in the Hypertension Detection and Follow-up Program. , 1986, American journal of preventive medicine.

[7]  H. Black,et al.  Treatment of mild hypertension. The more things change... , 1993, JAMA.

[8]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[9]  R. Prineas,et al.  Baseline electrocardiographic characteristics of the hypertensive participants , 1983 .

[10]  W. Kannel,et al.  Evaluation of cardiovascular risk in the elderly: the Framingham study. , 1978, Bulletin of the New York Academy of Medicine.